BCG vaccine nesting birds and rusted electrical conduits. The resulting closure of the plant for over two years resulting in shortages of bladder cancer and tuberculosis vaccines. On October 29, 2014 Health Canada gave the permission for Sanofi to resume production of BCG. The global supply situation was analyzed in 2017 and concluded that the global supply is sufficient to meet forecasted BCG vaccine demand but risks for shortages remain mainly due to supply concentration. A weakened strain of bovine tuberculosis bacillus, "Mycobacterium bovis" is specially subcultured in a culture medium, usually Middlebrook 7H9. Some BCG vaccines are freeze dried and become
Inoculation theory opinion. These contexts include: politics (e.g., Pfau et al., 1990; see Compton & Ivanov, 2013, for a review), health campaigns (e.g., Pfau & VanBockern, 1994; see Compton, Jackson, & Dimmock, 2016, for a review), marketing (e.g., Compton & Pfau, 2004) and education (Compton, 2011), among others. (See Banas & Rains, 2010, for a meta-analysis, and Compton, 2013, for a narrative overview.) The inoculation process is analogous to the medical inoculation process from which it draws its name; the analogy served as the inaugural exemplar for how inoculation confers resistance. As McGuire (1961) initially explained, medical inoculation works by exposing the